Increasing Prevalence of Type 2 Diabetes to Drive Asia Pacific Type 2 Diabetes Therapeutics Market to US $10.5 Billion by 2020
Type 2 diabetes is a major public health concerns in both the developed as well as the developing countries in the Asia Pacific. According to the International Diabetes Federation, nearly 387 million people around the world have diabetes and majority of these cases will be Type 2 diabetes.
Albany, NY -- (SBWire) -- 09/03/2015 --Market Research Reports Search Engine (MRRSE) has announced the addition of a market study to its rapidly expanding collection. The new report discusses the type 2 diabetes therapeutics market in Asia Pacific. The report focuses on the four major countries in Asia Pacific – China, India, Australia, Japan – to provide an accurate snapshot of the Asia Pacific market for type 2 diabetes therapeutics. The new report, titled ' Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth', is authored by GBI Research and presents detailed historical statistics regarding the Asia Pacific type 2 diabetes therapeutics market. It then examines the trends determining the present dynamics of the market and projects future market forecasts based on the same.
Browse Full Report with TOC @ http://www.mrrse.com/type-2-diabetes-therapeutics-in-asia-pacific-markets
The report predicts that, aided by the growing prevalence of type 2 diabetes in India and China, the Asia Pacific type 2 diabetes therapeutics market is set to grow to a value of US$10.5 billion by 2020, at a CAGR of 7.1% from its 2013 market value of US$6.5 billion.
The report segments the Asia Pacific type 2 diabetes therapeutics market by product type and geography. Both currently marketed and pipeline therapeutics are profiled in the report. DPP-4 inhibitors such as Januvia and Tradjenta, GLP-1 agonists such as Lyxumia and Victoza, sulfonylureas such as Gliclazide and Glimepiride, thiazolidinediones such as Actos, long-acting insulins such as Levemir and Lantus, and SGLT inhibitors such as Forxiga and Invokana are the major product categories within the Asia Pacific type 2 diabetes therapeutics market.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/130
The report presents in-depth data about the major national markets in the type 2 diabetes therapeutics market in Asia Pacific: China, India, Australia, and Japan. The report presents historical data charting the progress of the market in each country and forecasts for the market's expected growth from 2013 to 2020. Data regarding revenue and volume sales achieved by each of the main product types of type 2 diabetes therapeutics in each national market is presented in the report, for a comprehensive understanding of the market dynamics in each major market.
Pipeline products in the Asia Pacific type 2 diabetes therapeutics market are studied according to molecule type, phase distribution, program type, molecular target, and mechanism of action. The report explains the effect of the growing government approval for new classes of drugs such as SGLT inhibitors and GLP-1 agonists as the prime growth drivers for the Asia Pacific type 2 diabetes therapeutics market.
Browse Press Release @ http://www.mrrse.com/type-2-diabetes-therapeutics-in-asia-pacific-market-report
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
Media Relations Contact
Mr. Nachiket Ghumare
View this press release online at: http://rwire.com/622410